Molecular Subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements

Neoplasia (United States)

Volumn 14, Issue 7, 2012, Pages 600-611

  Paulo, Paula ^a,b,c   Ribeiro, Franclim R ^a,b,c   Santos, Joana ^a   Mesquita, Diana ^a   Almeida, Mafalda ^a   Barros Silva, João D ^a   Itkonen, Harri ^d   Henrique, Rui ^a,b   Jerónimo, Carmen ^a,b   Sveen, Anita ^b,c   Mills, Ian G ^b,d   Skotheim, Rolf I ^b,c   Lothe, Ragnhild A ^a,c   Teixeira, Manuel R ^a,c,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ATPASE AMINOPHOSPHOLIPID TRANSPORTER LIKE 1; BISULFITE; FK506 BINDING PROTEIN 10; GLYCINE N ACYLTRANSFERASE LIKE 2; HLA DM ANTIGEN; PHOSPHODIESTERASE III; PHOSPHOLIPASE A1; PROTEIN; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRICHOSTATIN A; TUDOR DOMAIN CONTAINING PROTEIN 1; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA MICROARRAY; DNA SEQUENCE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; WESTERN BLOTTING;

EID: 84865619515     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12600     Document Type: Article

References (56)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
2. Clark JP and Cooper CS (2009). ETS gene fusions in prostate cancer. Nat Rev Urol 6, 429-439.
3. Kumar-Sinha C, Tomlins SA, and Chinnaiyan AM (2008). Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8, 497-511.
4. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, et al. (2008). A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68, 7629-7637.
5. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, et al. (2008). Characterization of TMPRSS2: ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68, 73-80.
6. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, and Trapman J (2008). Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 68, 3094-3098.
7. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, et al. (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66, 3396-3400.
8. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, and Teixeira MR (2012). FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 51, 240-249.
9. Uren A and Toretsky JA (2005). Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 1, 521-528.
10. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, and Kallioniemi O (2010). FZD4 as a mediator of ERG oncogeneinduced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70, 6735-6745.
11. Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, et al. (2011). ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 11, 410-417.
12. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188.
13. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Zielvan der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, et al. (2008). Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68, 7541-7549.
14. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599.
15. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, and Shemshedini L (2007). ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21, 1835-1846.
16. Wang J, Cai Y, Ren C, and Ittmann M (2006). Expression of variant TMPRSS2/ ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66, 8347-8351.
17. Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K, Shimizu N, Kola I, and Hertzog PJ (2004). Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 324, 65-77.
18. Wang J, Cai Y, Yu W, Ren C, Spencer DM, and Ittmann M (2008). Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68, 8516-8524.
19. Schmittgen TD and Livak KJ (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101-1108.
20. Pearson H and Stirling D (2003). DNA extraction from tissue. Methods Mol Biol 226, 33-34.
21. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, and Laird PW (2000). MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28, E32.
22. Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F, Teixeira MR, and Jeronimo C (2010). Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 5, 343-351.
23. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, et al. (2010). Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16, 5842-5851.
24. Barros R, da Costa LT, Pinto-de-Sousa J, Duluc I, Freund JN, David L, and Almeida R (2011). CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype. Gut 60, 290-298.
25. Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, et al. (2011). Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One 6, e22317.
26. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
27. Sandelin A, Wasserman WW, and Lenhard B (2004). ConSite: Web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 32, W249-W252.
28. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al. (2010). Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29, 2147-2160.
29. Massie CE and Mills IG (2011). Global identification of androgen response elements. Methods Mol Biol 776, 255-273.
30. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
31. Loriot A, Boon T, and De Smet C (2003). Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer 105, 371-376.
32. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, and Gerald WL (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113, 913-923.
33. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, et al. (2009). Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 103, 1256-1269.
34. Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C, et al. (2008). Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn 10, 50-57.
35. Washington MN and Weigel NL (2010). 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 151, 1409-1417.
36. Chuma S, Hosokawa M, Kitamura K, Kasai S, Fujioka M, Hiyoshi M, Takamune K, Noce T, and Nakatsuji N (2006). Tdrd1/Mtr-1, a tudor-related gene, is essential for male germ-cell differentiation and nuage/germinal granule formation in mice. Proc Natl Acad Sci USA 103, 15894-15899.
37. Kojima K, Kuramochi-Miyagawa S, Chuma S, Tanaka T, Nakatsuji N, Kimura T, and Nakano T (2009). Associations between PIWI proteins and TDRD1/ MTR-1 are critical for integrated subcellular localization in murine male germ cells. Genes Cells 14, 1155-1165.
38. Wang J, Saxe JP, Tanaka T, Chuma S, and Lin H (2009). Mili interacts with tudor domain-containing protein 1 in regulating spermatogenesis. Curr Biol 19, 640-644.
39. Reuter M, Chuma S, Tanaka T, Franz T, Stark A, and Pillai RS (2009). Loss of the Mili-interacting tudor domain-containing protein-1 activates transposons and alters the Mili-associated small RNA profile. Nat Struct Mol Biol 16, 639-646.
40. Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, and Kallioniemi OP (2008). Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123, 2774-2781.
41. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, et al. (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66, 10242-10246.
42. Patterson CE, Schaub T, Coleman EJ, and Davis EC (2000). Developmental regulation of FKBP65. An ER-localized extracellular matrix binding-protein. Mol Biol Cell 11, 3925-3935.
43. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, and Golub TR (2005). Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 173, 1772-1777.
44. Periyasamy S, Warrier M, Tillekeratne MP, Shou W, and Sanchez ER (2007). The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 148, 4716-4726.
45. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, and Verreman K (2006). The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766, 79-87.
46. Hollenhorst PC, Shah AA, Hopkins C, and Graves BJ (2007). Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 21, 1882-1894.
47. Chao C, Ives K, Hellmich HL, Townsend CM Jr, and Hellmich MR (2009). Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression. J Surg Res 156, 26-31.
48. Fleischmann A, Waser B, and Reubi JC (2009). High expression of gastrinreleasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications. Endocr Relat Cancer 16, 623-633.
49. Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, and Chung DH (2008). Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci USA 105, 12891-12896.
50. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Muntener M, and Kristiansen G (2012). Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 72, 318-325.
51. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, and Siegfried JM (2005). Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7, 426-431.
52. de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, and de Jong M (2007). Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 48, 88-93.
53. Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, and de Jong M (2010). Androgenregulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer 126, 2826-2834.
54. Loberg RD, St John LN, Day LL, Neeley CK, and Pienta KJ (2006). Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 24, 161-168.
55. Olea N, Sakabe K, Soto AM, and Sonnenschein C (1990). The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126, 1457-1463.
56. Blanchere M, Berthaut I, Portois MC, Mestayer C, and Mowszowicz I (1998). Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J Steroid Biochem Mol Biol 66, 319-326